Manganese-Catalyzed Asymmetric Oxidation of Methylene C–H of Spirocyclic Oxindoles and Dihydroquinolinones with Hydrogen Peroxide
作者:Bin Qiu、Daqian Xu、Qiangsheng Sun、Jin Lin、Wei Sun
DOI:10.1021/acs.orglett.8b03652
日期:2019.2.1
A highly efficient strategy for the enantioselective oxidation of methylene C–H of spirocyclic oxindoles and dihydroquinolinones has been established, in which an earth-abundant manganesecatalyst and hydrogenperoxide are used. Noteworthy, the manganesecatalyst can be applied to the asymmetric hydroxylation of spirocyclic 2,3-dihydroquinolin-4-ones with 94–99% ee.
Aerobic Dehydrogenative Aromatization in the Preparation of 4-Aminoquinoline Derivatives by Synergistic Pd/Cu Catalysis
作者:Fei Chen、Huidan Geng、Chun Li、Jianta Wang、Bing Guo、Lei Tang、Yuan-Yong Yang
DOI:10.1021/acs.joc.3c01400
日期:2023.11.17
The 4-aminoquinoline moiety is widely present in various bioactive compounds and marketed drugs, while the preparation of this target structure relies heavily on the amination of 4-chloroquinolines. Herein, an atom and step economic procedure was developed based on an aerobic dehydrogenative aromatization strategy. Unlike the well-known palladium-catalyzed dehydrogenative aromatization of cyclohexanones
4-氨基喹啉部分广泛存在于各种生物活性化合物和市售药物中,而该目标结构的制备很大程度上依赖于4-氯喹啉的胺化。在此,基于有氧脱氢芳构化策略开发了原子和步骤经济程序。与众所周知的钯催化环己酮与胺的脱氢芳构化不同,协同 Pd/Cu 催化对于 2,3-二氢喹啉-4(1 H )-one 类型的底物至关重要。在优化条件下,一系列芳香族/脂肪族胺和2,3-二氢喹啉-4(1H ) -酮偶联,以中等到高收率得到相应的4-氨基喹啉产物,并应用当前的方法还展示了上市药物的制备和后期多样化。
Structure-activity relationships of antimalarial indolo[3,2-c]quinolines [1, 2]
作者:LM Werbel、SJ Kesten、WR Turner
DOI:10.1016/0223-5234(93)90036-e
日期:1993.1
Structure-activity relationships have been ascertained and chemical methodology developed for a series of antimalarial 3-chloroindolo[3,2-c]quinoline-5-oxides. The basic side chain as well as the ring N-oxide are critical for antimalarial activity as is a bromine or chlorine in position 3. Substitution at positions 7, 8, 9, 10 is not essential, although the most potent analog in our studies was the 8-nitro compound 4vv.
[EN] COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS COVALENTS D'EGFR ET LEURS MÉTHODES D'UTILISATION
申请人:[en]DANA-FARBER CANCER INSTITUTE, INC.
公开号:WO2023069959A1
公开(公告)日:2023-04-27
The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.